Shares of Dyax Corp. (NASDAQ:DYAX), a biopharma company focused on developing treatments for rare blood disorders, fell more than 13% during September.
Given the share price weakness, is now a good time to considering making an investment in Dyax? See below for my take.
Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.